Followers | 1321 |
Posts | 26908 |
Boards Moderated | 6 |
Alias Born | 12/10/2012 |
Thursday, October 14, 2021 9:08:07 AM
Now at $3.17
https://www.xortx.com/2021/10/13/xortx-therapeutics-announces-pricing-of-us12-million-public-offering-and-nasdaq-listing/
GO $XRTX
**************************************************************
XORTX Therapeutics Announces Pricing of US$12 Million Public Offering and Nasdaq Listing
CALGARY, Alberta, Oct. 13, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces the pricing of an underwritten public offering of 2,906,000 units (“Units”), with each Unit consisting of one common share, no par value, and one warrant (“Warrant”) to purchase one common share at a public offering price of US$4.13 per Unit, for aggregate gross proceeds of approximately US$12 million, prior to deducting underwriting discounts and other offering expenses and excluding any exercise of the underwriters’ option to purchase any additional securities as described herein (the “Offering”). The common shares and warrants contained in the Units are immediately separable upon issuance. The warrants have an initial exercise price of US$4.77 per share, will be immediately exercisable, and will have a term of approximately five years. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 435,900 common shares and/or warrants to purchase up to an additional 435,900 common shares at the Offering price less the underwriting discounts. The Company has received conditional approval to list its common shares on the Nasdaq Capital Market (“Nasdaq”) under the symbol “XRTX” and is expected to begin trading today. The Offering is expected to close on or about October 15, 2021, subject to satisfaction of customary closing conditions.
A.G.P./Alliance Global Partners is acting as sole book-running manager for the Offering.
The U.S. Securities and Exchange Commission (the “SEC”) declared effective a registration statement on Form F-1 relating to these securities on October 12, 2021. A final prospectus relating to the Offering will be filed with the SEC. The Offering is being made only by means of a prospectus. Copies of the final prospectus relating to the Offering may be obtained, when available, by contacting A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by email at prospectus@allianceg.com. Investors may also obtain these documents at no cost by visiting the SEC’s website at https://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.
For further information, please contact:
Allen Davidoff, CEO Nick Rigopulos, Director of Communications
adavidoff@xortx.com or +1 403 455 7727 nick@alpineequityadv.com or +1 617 901 0785
Dr. David Sans, Head of Corporate Development in New York City
dsans123@xortx.com or +1 347 573 0541
Recent XRTX News
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:10:54 PM
- XORTX Reprices Warrants Issued in Connection with Previous Private Placements • GlobeNewswire Inc. • 04/30/2024 05:54:49 PM
- XORTX Announces Publication of Key Research in ADPKD • GlobeNewswire Inc. • 04/22/2024 11:00:00 AM
- XORTX Welcomes New Member to the Board of Directors • GlobeNewswire Inc. • 04/08/2024 11:30:00 AM
- XORTX Announces Participation in Spring 2024 Investor Conferences • GlobeNewswire Inc. • 04/08/2024 11:00:00 AM
- XORTX Announces New Clinical Advisory Board Member • GlobeNewswire Inc. • 03/27/2024 09:00:00 AM
- XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial • GlobeNewswire Inc. • 03/19/2024 09:00:00 AM
- XORTX Reprices Warrants Issued in Connection with Previous Private Placements • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units • GlobeNewswire Inc. • 03/04/2024 12:00:00 PM
- XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units • GlobeNewswire Inc. • 02/15/2024 12:00:00 PM
- XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units • GlobeNewswire Inc. • 02/02/2024 01:46:09 AM
- XORTX Announces $2 Million Public Offering • GlobeNewswire Inc. • 01/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/03/2024 12:25:58 PM
- XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/02/2024 01:12:44 PM
- XORTX Welcomes New Member to the Board of Directors • GlobeNewswire Inc. • 01/02/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/30/2023 09:04:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/30/2023 12:30:05 PM
- XORTX Announces US ATM Offering • GlobeNewswire Inc. • 11/30/2023 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/30/2023 02:57:42 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 12:00:05 PM
- XORTX Meets Nasdaq Continued Listing Requirements • GlobeNewswire Inc. • 11/29/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 12:00:11 PM
- XORTX Clarifies Timing for Share Consolidation • GlobeNewswire Inc. • 11/10/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/08/2023 10:00:08 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM